Biotecnología microbiana y salud

Keyphrases

1. Breast Cancer 100%
2. Tumor-infiltrating Lymphocytes 72%
3. Peruvian 69%
4. Peru 46%
5. Protease 40%
6. Bovine Chromaffin Cells 36%
7. Triple-negative Breast Cancer 34%
8. Nicotine 32%
9. Nicotinic Receptors 30%
10. Oncology Biomarkers 28%
11. Immuno-oncology 28%
12. Erythrina Edulis 27%
13. Response Surface Methodology 27%
14. Extremophilic 27%
15. Hydrolyzate 25%
16. Alcalase 25%
17. Breast Cancer Patients 22%
18. Hydrolysis 22%
19. Indigenous Americans 21%
20. Overall Survival 21%
21. PIK3CA mutation 21%
22. Stromal Tumor-infiltrating Lymphocytes 21%
23. Seed Storage Proteins 20%
24. Tumor 19%
25. Residual Disease 19%
26. Glioblastoma 19%
27. Human Epidermal Growth Factor Receptor 2 (HER2) 19%
28. Catecholamine Secretion 18%
29. Tumor-infiltrating Immune Cells 18%
30. Avibacterium Paragallinarum 18%
31. Process Conditions 18%
32. Capsicum Annuum 18%
33. Fermentation Process Optimization 18%
34. Chili Pepper 18%
35. Phase II Trial 18%
36. Breast Cancer Subtypes 18%
37. Distillers Dried Grains with Solubles 18%
38. Pseudomonas Aeruginosa (P. aeruginosa) 18%
39. Chenopodium Pallidicaule 18%
40. Chromaffin Cells 18%
41. Molecular Characterization 17%
42. Inward Current 16%
43. Albumin 15%
44. Pepper Fruits 15%
45. Oxidative Stress 15%
46. ATP Secretion 14%
47. Functional Peptides 13%
48. Triple Negative 13%
49. Early Breast Cancer 12%
50. Pathologist 12%
51. Clinical Trials 12%
52. Acidification Rate 12%
53. Metabolic Alterations 12%
54. Programmed Death-ligand 1 (PD-L1) 12%
55. Odds Ratio 12%
56. Antioxidant Peptides 12%
57. Protein Concentrate 12%
58. Radiotherapy 12%
59. Serine Protease 11%
60. Neoadjuvant 11%
61. Microorganisms 11%
62. Ornithobacterium Rhinotracheale 11%
63. Lupinus mutabilis 11%
64. Cancer Control 11%
65. Hydrolysate 11%
66. Degree of Hydrolysis 11%
67. Neoadjuvant Therapy 11%
68. Fast Component 10%
69. Slow Component 10%
70. Depolarization 10%
71. Alzheimer's Disease 10%
72. Soluble Protein 10%
73. Salterns 10%
74. Confidence Interval 10%
75. Proteolytic Activity 10%
76. Risk Management 10%
77. Malignancy 10%
78. Prognostic Factors 10%
79. Neoadjuvant Chemotherapy 10%
80. 16S rRNA Gene 9%
81. Anthracyclines 9%
82. Lymphocyte Level 9%
83. Polymorphism 9%
84. Chronic Disease 9%
85. Functional Food 9%
86. Nutraceuticals 9%
87. MINDACT 9%
88. Genomic Risk 9%
89. CD163 9%
90. EORTC 9%
91. Docetaxel 9%
92. Saline Environment 9%
93. Enterobacter 9%
94. Genetic Epidemiology 9%
95. Tarwi 9%
96. Recombinant 9%
97. Extracellular Calcium 9%
98. Enzyme Activity 9%
99. Risk Management Framework 9%
100. Everyday Practices 9%